当前位置: 首页 >> 检索结果
4648. Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
作者: Nathália N Chamma-Siqueira.;Suiane C Negreiros.;Sarah-Blythe Ballard.;Sâmela Farias.;Sandro P Silva.;Stella M Chenet.;Eduardo J M Santos.;Luann W Pereira de Sena.;Flávia Póvoa da Costa.;Amanda G N Cardoso-Mello.;Paola B Marchesini.;Cássio R L Peterka.;Giselle M R Viana.;Alexandre Macedo de Oliveira.
来源: N Engl J Med. 2022年386卷13期1244-1253页
In most of the Americas, the recommended treatment to prevent relapse of Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body weight, despite evidence of only moderate efficacy.
4649. Single-Incision Mini-Slings for Stress Urinary Incontinence in Women.
作者: Mohamed Abdel-Fattah.;David Cooper.;Tracey Davidson.;Mary Kilonzo.;Md Hossain.;Dwayne Boyers.;Kiron Bhal.;Judith Wardle.;James N'Dow.;Graeme MacLennan.;John Norrie.
来源: N Engl J Med. 2022年386卷13期1230-1243页
Until recently, synthetic midurethral slings (made of mesh or tape) were the standard surgical treatment worldwide for female stress urinary incontinence, if conservative management failed. Data comparing the effectiveness and safety of newer single-incision mini-slings with those of standard midurethral slings are limited.
4650. Early Outpatient Treatment for Covid-19 with Convalescent Plasma.
作者: David J Sullivan.;Kelly A Gebo.;Shmuel Shoham.;Evan M Bloch.;Bryan Lau.;Aarthi G Shenoy.;Giselle S Mosnaim.;Thomas J Gniadek.;Yuriko Fukuta.;Bela Patel.;Sonya L Heath.;Adam C Levine.;Barry R Meisenberg.;Emily S Spivak.;Shweta Anjan.;Moises A Huaman.;Janis E Blair.;Judith S Currier.;James H Paxton.;Jonathan M Gerber.;Joann R Petrini.;Patrick B Broderick.;William Rausch.;Marie-Elena Cordisco.;Jean Hammel.;Benjamin Greenblatt.;Valerie C Cluzet.;Daniel Cruser.;Kevin Oei.;Matthew Abinante.;Laura L Hammitt.;Catherine G Sutcliffe.;Donald N Forthal.;Martin S Zand.;Edward R Cachay.;Jay S Raval.;Seble G Kassaye.;E Colin Foster.;Michael Roth.;Christi E Marshall.;Anusha Yarava.;Karen Lane.;Nichol A McBee.;Amy L Gawad.;Nicky Karlen.;Atika Singh.;Daniel E Ford.;Douglas A Jabs.;Lawrence J Appel.;David M Shade.;Stephan Ehrhardt.;Sheriza N Baksh.;Oliver Laeyendecker.;Andrew Pekosz.;Sabra L Klein.;Arturo Casadevall.;Aaron A R Tobian.;Daniel F Hanley.
来源: N Engl J Med. 2022年386卷18期1700-1711页
Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain.
4651. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
作者: Brett King.;Manabu Ohyama.;Ohsang Kwon.;Abraham Zlotogorski.;Justin Ko.;Natasha A Mesinkovska.;Maria Hordinsky.;Yves Dutronc.;Wen-Shuo Wu.;Jill McCollam.;Chiara Chiasserini.;Guanglei Yu.;Sarah Stanley.;Katrin Holzwarth.;Amy M DeLozier.;Rodney Sinclair.; .
来源: N Engl J Med. 2022年386卷18期1687-1699页
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokine signaling implicated in the pathogenesis of alopecia areata.
4657. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
作者: Edson D Moreira.;Nicholas Kitchin.;Xia Xu.;Samuel S Dychter.;Stephen Lockhart.;Alejandra Gurtman.;John L Perez.;Cristiano Zerbini.;Michael E Dever.;Timothy W Jennings.;Donald M Brandon.;Kevin D Cannon.;Michael J Koren.;Douglas S Denham.;Mezgebe Berhe.;David Fitz-Patrick.;Laura L Hammitt.;Nicola P Klein.;Haylene Nell.;Georgina Keep.;Xingbin Wang.;Kenneth Koury.;Kena A Swanson.;David Cooper.;Claire Lu.;Özlem Türeci.;Eleni Lagkadinou.;Dina B Tresnan.;Philip R Dormitzer.;Uğur Şahin.;William C Gruber.;Kathrin U Jansen.; .
来源: N Engl J Med. 2022年386卷20期1910-1921页
Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic. In light of reports of waning protection occurring 6 months after the primary two-dose vaccine series, data are needed on the safety and efficacy of offering a third (booster) dose in persons 16 years of age or older.
|